SOURCE: La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company

January 29, 2014 08:00 ET

La Jolla Pharmaceutical Company Announces Listing of Common Stock on the NASDAQ Capital Market

SAN DIEGO, CA--(Marketwired - Jan 29, 2014) - La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has received approval to list its common stock on The NASDAQ Capital Market. The Company's shares will trade on The NASDAQ Capital Market when the market opens today, Wednesday, January 29, 2014. As previously announced, in support of the Company's listing on NASDAQ, the Company effected a 1-for-50 reverse stock split on January 13, 2014. The Company currently has 4,483,740 shares of common stock issued and outstanding; on a fully diluted basis there would be approximately 17 million shares outstanding. The ticker symbol will return back to LJPC effective with the open of trading today.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. For more information on the Company please visit

About NASDAQ OMX Group

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit

Contact Information

  • Company Contact

    George F. Tidmarsh, M.D., Ph.D.
    President & Chief Executive Officer
    La Jolla Pharmaceutical Company
    Phone: (858) 207-4264


    Chester S. Zygmont, III
    Director of Finance
    La Jolla Pharmaceutical Company
    Phone: (858) 207-4262